Navigation Links
Lenalidomide Gives New Hope To Chronic Lymphocytic Leukemia Patients

According to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI), patients treated with lenalidomide// for relapsed chronic lymphocytic leukemia (CLL) or diseases that no longer responded to chemotherapy have experienced a major response to the therapy. The results of this study were published in the December 1 issue of the Journal of Clinical Oncology.

"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.

Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.

In this phase II study – the first to report clinical activity of lenalidomide in patients with CLL – 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.

"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.



Source-Eurekalert
SR
'"/>




Page: 1

Related medicine news :

1. Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs
2. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
3. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
4. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
5. US Doctors Association Gives away $110,000 To NGO’
6. Woman In Coma Gives Birth To Daughter
7. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
8. New Eye Surgery Gives Hope To Short-Sighted
9. Jharkhand Gives Health industry status
10. WHO Gives Its Approval For Bird Flu Test Kit
11. FDA Gives Its Approval For Inhaler
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: